Literature DB >> 3197752

Pharmacokinetics of ranitidine in patients undergoing haemofiltration.

U Gladziwa1, D R Krishna, U Klotz, T H Ittel, H Schunkert, W M Glöckner, H Mann.   

Abstract

The pharmacokinetics of ranitidine was investigated in 11 patients with acute or end stage renal failure during haemofiltration. Each patient received 50 mg ranitidine i.v. The mean distribution and elimination half lives were 0.13 and 2.57 h, respectively. The total body clearance (CL) and volume of distribution (Vz) were 298 ml.min-1 (5.19 ml.min-1.kg-1) and 1.08 l.kg-1, respectively. About 17.1% of the administered dose was removed by haemofiltration (in approximately 20 l filtrate). Five of the patients still had some urine output and they excreted 0.1 to 11.8% of the dose in urine in 24 h. The haemofiltration clearance was 66.9 ml.min-1 at a filtrate flow rate of 86 ml.min-1, corresponding to a mean sieving coefficient of 0.78 (n = 6). As plasma concentrations were still in an effective range after haemofiltration, dose supplementation is not recommended.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3197752     DOI: 10.1007/bf00561377

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Pharmacokinetics and dynamics of famotidine in patients with renal failure.

Authors:  U Gladziwa; U Klotz; D R Krishna; H Schmitt; W M Glöckner; H Mann
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

2.  Famotidine and ranitidine control of 24 h intragastric acidity after single bedtime administration: a study using continuous pH monitoring.

Authors:  V Savarino; G S Mela; P Scalabrini; E Di Timoteo; M R Magnolia; G Percario; G Celle
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

3.  Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations.

Authors:  T A Golper; S K Wedel; A A Kaplan; A M Saad; S T Donta; E P Paganini
Journal:  Int J Artif Organs       Date:  1985-11       Impact factor: 1.595

4.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

5.  Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.

Authors:  A M van Hecken; T B Tjandramaga; A Mullie; R Verbesselt; P J de Schepper
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of ranitidine.

Authors:  C J Roberts
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

7.  Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis.

Authors:  D A Sica; T Comstock; A Harford; F Eshelman
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Ranitidine kinetics in normal subjects.

Authors:  N P Chau; P Y Zech; N Pozet; A Hadj-Aissa
Journal:  Clin Pharmacol Ther       Date:  1982-06       Impact factor: 6.875

9.  Plasma ranitidine concentrations after intravenous administration in normal volunteers and haemodialysis patients.

Authors:  A P Roberts; C Harrison; G T Dixon; J R Curtis
Journal:  Postgrad Med J       Date:  1983-01       Impact factor: 2.401

10.  Furan H2-antagonist ranitidine inhibits pentagastrin-stimulated gastric secretion stronger than cimetidine.

Authors:  W Domschke; G Lux; S Domschke
Journal:  Gastroenterology       Date:  1980-12       Impact factor: 22.682

View more
  7 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 2.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 3.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 4.  Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.

Authors:  U Gladziwa; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

5.  Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration.

Authors:  J M Kinowski; J E de la Coussaye; F Bressolle; D Fabre; G Saissi; O Bouvet; M Galtier; J J Eledjam
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 6.  Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.

Authors:  U Gladziwa; U Koltz
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

Review 7.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.